Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL645910 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL1255985 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL19253810 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL11153523 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL6573992 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL3688686 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL6572425 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL25283986 | 0.98 | DNM1 (0.49) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL727987 | 0.98 | DNM1 (0.49) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL6574079 | 0.98 | DNM1 (0.49) | MEN1KMT2AMAPK1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779585-B2 | Method for treating coronavirus infections | OYAGEN, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230285434-A1 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | OYAGEN, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11738025-B2 | Method for treating coronavirus infections | OYAGEN, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233591-A1 | METHOD FOR TREATING POXVIRIDAE INFECTIONS | OYAGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-4100019-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | Oyagen Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220378815-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | OYAGEN, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2021211757-A1 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | OYAGEN, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211759-A1 | METHOD FOR TREATING POXVIRIDAE INFECTIONS | OYAGEN, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021158701-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | OYAGEN, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158248-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | OYAGEN, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210236497-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | OYAGEN, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-10542748-B2 | Stabilized antimicrobial compositions and methods of use | ISOKLEAN LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190090481-A1 | STABILIZED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ISOKLEAN LLC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20170238542-A1 | STABILIZED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ISOKLEAN LLC (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285434-A1 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | MPO, LIPA, CAT | CHRM2 4829/4885CHRM1 4844/4885CHRM3 4312/4885 |
| US-11779585-B2 | Method for treating coronavirus infections | ACE2, ACE, SARS1 | CHRM2 2075/4885CHRM1 3598/4885CHRM3 709/4885 |
| US-20170238542-A1 | STABILIZED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | CAPG, AP2S1, YTHDC1 | CHRM2 1533/4885CHRM1 1045/4885CHRM3 3333/4885 |
| US-20220378815-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | CHRM2 2075/4885CHRM1 3598/4885CHRM3 709/4885 |
| US-20210236497-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | CHRM2 2171/4885CHRM1 3531/4885CHRM3 669/4885 |
| US-11738025-B2 | Method for treating coronavirus infections | ACE2, ACE, SARS1 | CHRM2 2171/4885CHRM1 3531/4885CHRM3 669/4885 |
| US-20190090481-A1 | STABILIZED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | CXCL8, MLST8, USP8 | CHRM2 2120/4885CHRM1 1669/4885CHRM3 3576/4885 |
| US-20230233591-A1 | METHOD FOR TREATING POXVIRIDAE INFECTIONS | ITPA, VAC14, MAVS | CHRM2 4183/4885CHRM1 4382/4885CHRM3 3633/4885 |
| US-10542748-B2 | Stabilized antimicrobial compositions and methods of use | YTHDC1, AOC1, YTHDF1 | CHRM2 2460/4885CHRM1 2292/4885CHRM3 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.